The present invention relates to a compound according to Formula (I) wherein R.sup.1 is a hydrocarbyl group selected from the group consisting of alkyl, alkenyl, aryl, aralkyl, and alkylaryl groups, and one or more combinations thereof; wherein R.sup.2 is a hydrogen atom, an aryl group or an alkyl group; and wherein R.sup.3, R.sup.4, R.sup.5 and R.sup.6, are the same or different and are each independently a hydrogen atom, a halogen atom, a cyano group, an amino group, a hydrocarbyl group selected from the group consisting of alkyl, alkenyl, aryl, aralkyl, and alkylaryl groups or an alkoxy group, and one or more combinations thereof as internal electron donor and to a process for the synthesis of a compound according to Formula (I), wherein R.sup.1 is a hydrocarbyl group selected from the group consisting of alkyl, alkenyl, aryl, aralkyl, alkoxycarbonyl and alkylaryl groups, and one or more combinations thereof; wherein R.sup.2 is a hydrogen atom or an alkyl group; wherein R.sup.3, R.sup.4, R.sup.5 and R.sup.6, are the same or different and are each independently selected from a group consisting of a hydrogen atom; a hydrocarbyl, preferably, said process comprising the step of reacting a compound according to Formula (II) [R.sup.1C(O)Cl] with a compound according to Formula (III) to obtain the compound according to Formula (I) and to the use of these compounds as internal donor in Ziegler-Natta catalysis of olefins. ##STR00001##

The present invention relates to a compound according to Formula (I) wherein R.sup.1 is a hydrocarbyl group selected from the group consisting of alkyl, alkenyl, aryl, aralkyl, and alkylaryl groups, and one or more combinations thereof; wherein R.sup.2 is a hydrogen atom, an aryl group or an alkyl group; and wherein R.sup.3, R.sup.4, R.sup.5 and R.sup.6, are the same or different and are each independently a hydrogen atom, a halogen atom, a cyano group, an amino group, a hydrocarbyl group selected from the group consisting of alkyl, alkenyl, aryl, aralkyl, and alkylaryl groups or an alkoxy group, and one or more combinations thereof as internal electron donor and to a process for the synthesis of a compound according to Formula (I), wherein R.sup.1 is a hydrocarbyl group selected from the group consisting of alkyl, alkenyl, aryl, aralkyl, alkoxycarbonyl and alkylaryl groups, and one or more combinations thereof; wherein R.sup.2 is a hydrogen atom or an alkyl group; wherein R.sup.3, R.sup.4, R.sup.5 and R.sup.6, are the same or different and are each independently selected from a group consisting of a hydrogen atom; a hydrocarbyl, preferably, said process comprising the step of reacting a compound according to Formula (II) [R.sup.1C(O)Cl] with a compound according to Formula (III) to obtain the compound according to Formula (I) and to the use of these compounds as internal donor in Ziegler-Natta catalysis of olefins. ##STR00001##

GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure:

##STR00001##

wherein R.sub.1a, R.sub.1b, R.sub.1c, R.sub.1d, R.sub.2, R.sub.2a, and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure:

##STR00001##

wherein R.sub.1a, R.sub.1b, R.sub.1c, R.sub.1d, R.sub.2, R.sub.2a, and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

Provided is a method for producing an optically active substance, the method including an asymmetric induction, wherein an asymmetry inducer is allowed to act on a chiral molecule having a half-life of enantiomeric excess of shorter than 10 hours, thereby increasing abundance of one enantiomer of the chiral molecule. According to this method, one enantiomer of a chiral molecule that is susceptible to racemization can be selectively and efficiently obtained.

Provided is a method for producing an optically active substance, the method including an asymmetric induction, wherein an asymmetry inducer is allowed to act on a chiral molecule having a half-life of enantiomeric excess of shorter than 10 hours, thereby increasing abundance of one enantiomer of the chiral molecule. According to this method, one enantiomer of a chiral molecule that is susceptible to racemization can be selectively and efficiently obtained.

An amide derivative represented by the following Formula (1) is provided as an amide derivative showing a significantly excellent effect for a pest control action. In the following Formula (1), A represents a carbon atom, a nitrogen atom, or the like, and K represents a non-metal atomic group necessary for forming a cyclic linking group derived from benzene or a heterocyclie. X represents a halogen atom or the like; n represents an integer of from 0 to 4. R.sub.1 and R.sub.2 represent hydrogen atoms, alkyl groups, or the like. T represents C(=G.sub.1)-Q.sub.1 or C(=G.sub.1)-G.sub.2Q.sub.2, and G.sub.1 to G.sub.3 each represent oxygen atoms or the like. Q.sub.1 and Q.sub.2 each represent a hydrogen atom, an alkyl group, an aryl group, or the like. Y.sub.1 and Y.sub.5 each represent a halogen atom or the like, Y.sub.2 and Y.sub.4 each represent a hydrogen atom or the like, and Y.sub.3 represents a C2-C5 haloalkyl group. ##STR00001##

An amide derivative represented by the following Formula (1) is provided as an amide derivative showing a significantly excellent effect for a pest control action. In the following Formula (1), A represents a carbon atom, a nitrogen atom, or the like, and K represents a non-metal atomic group necessary for forming a cyclic linking group derived from benzene or a heterocyclie. X represents a halogen atom or the like; n represents an integer of from 0 to 4. R.sub.1 and R.sub.2 represent hydrogen atoms, alkyl groups, or the like. T represents C(=G.sub.1)-Q.sub.1 or C(=G.sub.1)-G.sub.2Q.sub.2, and G.sub.1 to G.sub.3 each represent oxygen atoms or the like. Q.sub.1 and Q.sub.2 each represent a hydrogen atom, an alkyl group, an aryl group, or the like. Y.sub.1 and Y.sub.5 each represent a halogen atom or the like, Y.sub.2 and Y.sub.4 each represent a hydrogen atom or the like, and Y.sub.3 represents a C2-C5 haloalkyl group. ##STR00001##

The present invention relates to a novel compound showing leukotriene B4 receptor 2 (BLT2) inhibitory activity and a pharmaceutical composition, for preventing or treating inflammatory diseases, having same as an active ingredient. The inventors identified a novel compound containing BTL2 inhibitory activity, and experimentally confirmed that the present novel compound had an excellent effect on the enhancement of the cancer cell death, on the inhibition of the metastasis and chemotactic mobility, and on the anti-asthma activity. Therefore, the present novel compound can be used as a very effective pharmaceutical component for treating the inflammatory-related diseases.

The present invention relates to a novel compound showing leukotriene B4 receptor 2 (BLT2) inhibitory activity and a pharmaceutical composition, for preventing or treating inflammatory diseases, having same as an active ingredient. The inventors identified a novel compound containing BTL2 inhibitory activity, and experimentally confirmed that the present novel compound had an excellent effect on the enhancement of the cancer cell death, on the inhibition of the metastasis and chemotactic mobility, and on the anti-asthma activity. Therefore, the present novel compound can be used as a very effective pharmaceutical component for treating the inflammatory-related diseases.